To use all functions of this page, please activate cookies in your browser.
My watch list
my.chemeurope.com
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
SB649868SB649868 is an orexin receptor antagonist in development by GlaxoSmithKline. Currently in Phase 2 development, this drug for sleep disorders is one of two such compounds currently in development, the other being Actelion's ACT-078573. Additional recommended knowledgeGSK presentation
|
| This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "SB649868". A list of authors is available in Wikipedia. |
Last viewed
- Le groupe ACME et Hydrogenious LOHC Technologies explorent ensemble les chaînes de valeur de l'hydrogène d'Oman à l'Europe
- Category:Osmium
- A Record Year for ZEISS - In fiscal year 2020/21, ZEISS achieves highest revenue yet in its 175-year history at 7.5 billion euros
- Séparation d'échelle : décomposer les problèmes insolubles en problèmes solubles - L'ordinateur déterminera ce qu'il faut ignorer
- Levofloxacin
